CJC-1295 (without DAC / Mod GRF 1-29) vs Sermorelin

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

CJC-1295 (without DAC / Mod GRF 1-29)Sermorelin
CategoryPeptidesPeptides
Standard DoseResearch indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.
TimingBest administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.
Cycle Duration12-24 week cycles with 4-8 week breaks.12-24 week cycles. Some protocols use continuous treatment.
Evidence Levelmoderate_humanstrong_human

Mechanism

Mod GRF 1-29 (Modified Growth Hormone Releasing Factor, amino acids 1-29) is a truncated and modified GHRH analog that binds to GHRH receptors on anterior pituitary somatotrophs, activating cAMP via Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways. Without the DAC moiety, it has a short half-life of approximately 30 minutes, producing acute GH pulses that more closely mimic natural pulsatile GH secretion. It also stimulates pituitary gene transcription of GH mRNA, preserving endogenous pituitary reserve.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.

Cycle Duration

12-24 week cycles with 4-8 week breaks.

Side Effects

  • Flushing post-injection
  • Head rush
  • Hunger increase
  • Water retention (mild)
  • Tingling in extremities

Contraindications

  • Active cancer
  • Diabetic retinopathy
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6Hexarelin
B

Sermorelin

Peptides

Mechanism

Sermorelin is a synthetic 29-amino acid peptide representing the biologically active fragment of GHRH (amino acids 1-29) with full functional activity. It activates GHRH receptors on pituitary somatotrophs, stimulating cAMP production via Gs protein/adenylate cyclase and MAP kinase pathways. Due to the interactive effects of sermorelin and endogenous somatostatin, GH release is episodic rather than continuous. Sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing and preserving pituitary GH reserve.

Standard Dosing

Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.

Timing

Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.

Cycle Duration

12-24 week cycles. Some protocols use continuous treatment.

Side Effects

  • Injection site reactions
  • Facial flushing
  • Headache
  • Dizziness
  • Transient taste changes

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →